Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...

Dr Pradeep highlights warning signs of heart failure, including increased urination at night, swollen ankles, and breathlessness.

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

The number of US adults living with heart failure has more than doubled over the past three decades, mostly due to the rising ...

Martha Gulati, MD, explains how bias and underrepresentation in research lead to misdiagnosis of HFpEF in women and delays in ...

Ultromics, a pioneer in AI-driven cardiology solutions, today announced an investment from the American Heart Association's Go Red for Women Venture Fund, a fund within American Heart Association ...

Cytokinetics has announced that the FDA has approved MYQORZO tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with oHCM .

Aficamten, a first-in-class cardiac myosin inhibitor, offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed ...